-
Manabu Fujimoto,
Yasuhito Hamaguchi,
Kenzo Kaji,
Takashi Matsushita,
Yuki Ichimura,
Masanari Kodera, Naoko Ishiguro,
Ikuko Ueda-Hayakawa,
Yoshihide Asano,
Fumihide Ogawa, [......],
Eriko Mabuchi,
Kenji Hirose,
Narihiro Akimoto,
Naohito Hatta,
Kiyohiro Tsutsui,
Akira Higashi,
Atsuyuki Igarashi,
Mariko Seishima,
Minoru Hasegawa,
Kazuhiko Takehara
[show abstract]
[hide abstract]
ABSTRACT: To identify the 140-kd autoantigen recognized by anti-155/140 autoantibodies that are associated with adult cancer-associated dermatomyositis (DM) and juvenile DM and to determine the clinical relevance of anti-155/140 antibodies in a large cohort.
Sera from 456 DM patients were assessed for the presence of anti-155/140 antibodies by immunoprecipitation using K562 cell extracts as substrate. Using immunoprecipitation and Western blotting, we then examined whether anti-155/140-positive sera recognized transcription intermediary factor 1α (TIF-1α), TIF-1β, and TIF-1γ. The clinical associations of antigen reactivity were also evaluated.
Anti-155/140-positive sera reacted with 140-kd TIF-1α in addition to 155-kd TIF-1γ. Among sera from 456 DM patients, 52 were reactive with both TIF-1α and TIF-1γ, while another 25 were reactive with TIF-1γ alone. Additionally, 7 were reactive with TIF-1β. Malignancy was more frequently found in adult patients with both anti-TIF-1α and anti-TIF-1γ antibodies than in those with anti-TIF-1γ antibodies alone (73% versus 50%; P < 0.05). In addition to juvenile DM patients and middle-aged and older DM patients with high percentages of malignancy, 8 "young adult" DM patients without malignancy had these autoantibodies.
Anti-155/140 antibodies target TIF-1 family proteins, TIF-1α and TIF-1β, in addition to TIF-1γ. Since TIF-1 proteins have significant roles in oncogenesis, these antibodies may be produced during misdirected antitumor immunity.
Arthritis & Rheumatism 02/2012; 64(2):513-22. · 7.87 Impact Factor
-
Yuki Ichimura,
Takashi Matsushita,
Yasuhito Hamaguchi,
Kenzo Kaji,
Minoru Hasegawa,
Yoshinori Tanino,
Yayoi Inokoshi,
Kazuhiro Kawai,
Takuro Kanekura,
Maria Habuchi, [......],
Ayako Nishino, Naoko Ishiguro,
Naoki Sugimoto,
Rui Aoki,
Noriko Ando,
Tetsuya Abe,
Takashi Kanda,
Masataka Kuwana,
Kazuhiko Takehara,
Manabu Fujimoto
[show abstract]
[hide abstract]
ABSTRACT: Myositis-specific autoantibodies (MSAs) are useful tools for identifying clinically homogeneous subsets and predicting prognosis of patients with idiopathic inflammatory myopathies (IIM) including polymyositis (PM) and dermatomyositis (DM). Recent studies have shown that anti-NXP2 antibody (Ab) is a major MSA in juvenile dermatomyositis (JDM). In this study the frequencies and clinical associations of anti-NXP2 Ab were evaluated in adult patients with IIM.
Clinical data and serum samples were collected from 507 adult Japanese patients with IIM (445 with DM and 62 with PM). Eleven patients with JDM, 108 with systemic lupus erythematosus, 433 with systemic sclerosis and 124 with idiopathic pulmonary fibrosis were assessed as disease controls. Serum was examined for anti-NXP2 Ab by immunoprecipitation and western blotting using polyclonal anti-NXP2 Ab.
Seven patients (1.6%) with adult DM and one (1.6%) with adult PM were positive for anti-NXP2 Ab. Except for two patients with JDM, none of the disease controls were positive for this autoantibody. Among eight adult patients with IIM, three had internal malignancies within 3 years of diagnosis of IIM. Another patient with DM also had a metastatic cancer at the diagnosis. All of the carcinomas were at an advanced stage (stage IIIb-IV).
While less common than in juvenile IIM, anti-NXP2 Ab was found in adult IIM. Anti-NXP2 Ab may be associated with adult IIM with malignancy.
Annals of the rheumatic diseases 01/2012; 71(5):710-3. · 8.11 Impact Factor
-
Yasuhito Hamaguchi,
Masataka Kuwana,
Kana Hoshino,
Minoru Hasegawa,
Kenzo Kaji,
Takashi Matsushita,
Kazuhiro Komura,
Motonobu Nakamura,
Masanari Kodera,
Norihiro Suga, [......],
Yukihiro Umeda,
Masaaki Kawase,
Eriko Mabuchi,
Yoshihide Asano,
Kinuyo Sodemoto,
Mariko Seishima,
Hidehiro Yamada,
Shinichi Sato,
Kazuhiko Takehara,
Manabu Fujimoto
[show abstract]
[hide abstract]
ABSTRACT: To clarify the association of clinical and prognostic features with dermatomyositis (DM)-specific autoantibodies (Abs) in adult Japanese patients with DM.
Retrospective study.
Kanazawa University Graduate School of Medical Science Department of Dermatology and collaborating medical centers. Patients A total of 376 consecutive adult Japanese patients with DM who visited our hospital or collaborating medical centers between 2003 and 2008.
Clinical and laboratory characteristics of adult Japanese patients with DM and DM-specific Abs that include Abs against Mi-2, 155/140, and CADM-140.
In patients with DM, anti-Mi-2, anti-155/140, and anti-CADM-140 were detected in 9 (2%), 25 (7%), and 43 (11%), respectively. These DM-specific Abs were mutually exclusive and were detected in none of 34 patients with polymyositis, 326 with systemic sclerosis, and 97 with systemic lupus erythematosus. Anti-Mi-2 was associated with classical DM without interstitial lung disease or malignancy, whereas anti-155/140 was associated with malignancy. Patients with anti-CADM-140 frequently had clinically amyopathic DM and rapidly progressive interstitial lung disease. Cumulative survival rates were more favorable in patients with anti-Mi-2 compared with those with anti-155/140 or anti-CADM-140 (P < .01 for both comparisons). Nearly all deaths occurred within 1 year after diagnosis in patients with anti-CADM-140. Conclusion Dermatomyositis-specific Abs define clinically distinct subsets and are useful for predicting clinical outcomes in patients with DM.
Archives of dermatology 04/2011; 147(4):391-8. · 4.76 Impact Factor
